aller au contenu
Price indexes for clinical trial research : a feasibility study Aperçu de cet ouvrage
FermerAperçu de cet ouvrage
Vérifiant…

Price indexes for clinical trial research : a feasibility study

Auteur : Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
Éditeur : Cambridge, Mass. : National Bureau of Economic Research, 2013.
Collection : Working paper series (National Bureau of Economic Research), no. 18918.
Édition/format :   Livre électronique : Document : AnglaisVoir toutes les éditions et les formats
Base de données :WorldCat
Résumé :
We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose  Lire la suite...
Évaluation :

(pas encore évalué) 0 avec des critiques - Soyez le premier.

Sujets
Plus comme ceci

 

Trouver un exemplaire en ligne

Trouver un exemplaire dans la bibliothèque

&AllPage.SpinnerRetrieving; Recherche de bibliothèques qui possèdent cet ouvrage...

Détails

Type d’ouvrage : Document, Ressource Internet
Format : Ressource Internet, Fichier informatique
Tous les auteurs / collaborateurs : Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
Numéro OCLC : 835500084
Notes : Title from http://www.nber.org/papers/18918 viewed April 4, 2013.
"March 2013."
Description : 1 online resource (35 p.) : ill.
Titre de collection : Working paper series (National Bureau of Economic Research), no. 18918.
Responsabilité : Ernst R. Berndt, Iain M. Cockburn.

Résumé :

We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services.

Critiques

Critiques d’utilisateurs
Récupération des critiques de GoodReads...
Récuperation des critiques DOGObooks…

Tags

Soyez le premier.
Confirmez cette demande

Vous avez peut-être déjà demandé cet ouvrage. Veuillez sélectionner OK si vous voulez poursuivre avec cette demande quand même.

Données liées


<http://www.worldcat.org/oclc/835500084>
library:oclcnum"835500084"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/835500084>
rdf:typeschema:Book
schema:about
<http://id.loc.gov/authorities/subjects/sh2007003908>
rdf:typeschema:Intangible
schema:name"Research and development projects--Costs--Econometric models."
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:contributor
schema:creator
schema:datePublished"2013"
schema:description"We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1218425129>
schema:inLanguage"en"
schema:name"Price indexes for clinical trial research a feasibility study"
schema:publisher
schema:url
schema:url<http://www.nber.org/papers/w18918>

Content-negotiable representations

Fermer la fenêtre

Veuillez vous identifier dans WorldCat 

Vous n’avez pas de compte? Vous pouvez facilement créer un compte gratuit.